Central Laboratory Core

项目摘要-中央实验室核心 中心实验室(CL)核心伙伴关系评估病毒和免疫的首要目标 为艾滋病毒携带者提供带有肿瘤学的景观交叉口(展馆)将提供集中的 生物样本的生物库、病毒学和免疫学评估 拟议的翻译研究以及未来展馆试点项目。CL核心将由三人共同领导 特别调查员约翰·施奈德博士(南非)、兹瓦瓦赫拉·奇伦杰博士(津巴布韦)和 Tim Watboer(德国)，他们有互补的专业知识。CL联合领导人已经设计了一个强大的 灵活的管道和一系列分析方法，建立在基础设施和长期 展馆合作调查人员在南非、津巴布韦、 美国和德国。CL Core有目的地将这一独特的专业知识与 低收入和中等收入国家(LMIC)伙伴国家，以有效地促进与肿瘤和 病人的特征。这些知识可以为有效预防和癌症的发展提供信息。 减轻LMIC中艾滋病毒携带者(PLWH)癌症负担的治疗干预 不成比例地受到艾滋病毒的影响。为了实现总体目标，CL Core将提供集中的、 用于收集组织的终点判定、DNA和RNA提取、 HPV和EBV检测和基因分型，RNA表达分析，多重病毒血清学评估，以及 为拟议和未来的项目进行肿瘤微环境的免疫学评估。这些活动 被组织为以下目标： 目标1：作为南非和津巴布韦的集中生物库资源，供收集， 支持展馆研究的生物样品的加工和储存这一目标提供了生物库 LMIC环境中的高负担和研究不足的病毒癌症，包括非宫颈HPV相关的 癌症(肛门癌、口咽癌、阴道癌和外阴癌)和结膜癌，疑似但尚未确诊 PLWH中的病毒病原学不明。 目标2：提供生物检疫的集中病毒学和免疫学测试，以支持拟议的 未来Pavilion研究的目标是为银行样本提供集中的病毒和免疫学测试 通过四种强有力的分析方法支持拟议的和未来的研究目标 展馆合作机构，包括LMIC和非LMIC站点。 目标3：提供集中的专家病理学，以支持拟议和未来的展馆研究 AIM为银行组织标本提供全面和专家集中的病理判定 支持拟议的翻译研究和未来发展核心试点研究。

PROJECT SUMMARY – CENTRAL LABORATORY CORE The overarching goal of the Central Laboratory (CL) Core for the Partnership to Assess Viral and Immune Landscape Intersections with Oncology for People Living with HIV (PAVILION) is to provide centralized biobanking and virologic and immunologic assessment of well annotated biospecimens in support of the proposed translational studies as well as future PAVILION pilot projects. The CL Core will be co-led by three exceptional investigators, Drs. Johann Schneider (South Africa), Zvavahera (Mike) Chirenje (Zimbabwe), and Tim Waterboer (Germany), who have complementary expertise. The CL Co-Leaders have designed a robust yet flexible pipeline and range of analytical methodologies that builds upon the infrastructure and long-term international collaborations established by the PAVILION partnering investigators in South Africa, Zimbabwe, the US, and Germany. The CL Core purposefully pairs this unique expertise with established laboratories in the low- and middle-income country (LMIC) partner countries to efficiently advance knowledge related to tumor and patient characteristics. This knowledge can then inform the development of effective prevention and cancer treatment interventions to reduce the burden of cancer for people living with HIV (PLWH) in LMICs disproportionately impacted by HIV. To achieve the overarching goal, the CL Core will provide centralized, research-quality pathology evaluation for endpoint adjudication of collected tissues, DNA and RNA extraction, HPV and EBV detection and genotyping, RNA expression analysis, multiplex viral serology assessment, and immunological evaluation of the tumor microenvironment for the proposed and future projects. These activities are organized into the following Aims: Aim 1: Serve as a centralized biobanking resource in South Africa and Zimbabwe for the collection, processing, and storage of biospecimens in support of PAVILION studies This aim provides biobanking of high-burden and under-researched viral cancers in LMIC settings, including non-cervical HPV-associated cancers (anal, oropharyngeal, penile, and vulvar) and conjunctival cancer, with a suspected but as of yet unidentified viral etiology amongst PLWH. Aim 2: Provide centralized virologic and immunologic testing of biospecimens in support of proposed and future PAVILION studies This aim provides centralized viral and immunologic testing of banked specimens in support of proposed and future study aims through a robust set of analytical methodologies across four PAVILION partnering institutions, including LMIC and non-LMIC sites. Aim 3: Provide centralized expert pathology in support of proposed and future PAVILION studies This aim provides comprehensive and expert centralized pathology adjudication of banked tissue specimens in support of the proposed translational studies and future Developmental Core pilot studies.